Wilson reports 72-week data Wilson’s disease candidate

Wilson Therapeutics AB (SSE:WTX) reported data from 20 evaluable patients with Wilson’s disease in the extension portion of the 24-week Phase II WTX101-201 trial showing that once-daily oral Decuprate bis-choline tetrathiomolybdate (WTX101) controlled mean nonceruloplasmin-bound copper (NCC) levels through week 72 (0.9 µm at week 24 and 0.5 µm at week 72).

Additionally, WTX101 improved or maintained albumin levels, alanine aminotransferase (ALT) levels and Model for End-Stage Liver Disease (MELD) scores at week 72 compared with week 48, which the company said continues to indicate stability of liver function. WTX101 also led to continued improvements in Unified Wilson Disease Rating Scale (UWDRS) disability and neurologic scores at week 72 compared with week 24. Data were presented at the European Association for the Study of the Liver meeting in Paris...